ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 992,87
0,18%
Dow Jones
38 686,32
1,51%
DAX
18 497,94
-0,09%
Brent Oil
81,295
0,00%
Bitcoin
67 709,81
-0,02%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Altamira Therapeutics Ltd (CYTO)

  7. Altamira Therapeutics Ltd (CYTO) Actualités

CYTO

Altamira Therapeutics (CYTO)

Altamira Therapeutics Ltd
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:CYTO
DateHeureSourceTitreSymboleSociété
28/05/202416h31GlobeNewswire Inc.Altamira Therapeutics Provides Business UpdateNASDAQ:CYTOAltamira Therapeutics Ltd
23/05/202414h47GlobeNewswire Inc.Altamira Therapeutics Announces Dissemination of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis Through Social Media Channels of Top Allergy JournalNASDAQ:CYTOAltamira Therapeutics Ltd
16/05/202422h15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CYTOAltamira Therapeutics Ltd
01/05/202414h47GlobeNewswire Inc.Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and InflammationNASDAQ:CYTOAltamira Therapeutics Ltd
24/04/202414h47GlobeNewswire Inc.Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed JournalNASDAQ:CYTOAltamira Therapeutics Ltd
10/04/202414h00GlobeNewswire Inc.Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial ResultsNASDAQ:CYTOAltamira Therapeutics Ltd
04/04/202414h45GlobeNewswire Inc.Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024NASDAQ:CYTOAltamira Therapeutics Ltd
25/03/202413h47GlobeNewswire Inc.Altamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA VaccinesNASDAQ:CYTOAltamira Therapeutics Ltd
07/02/202414h47GlobeNewswire Inc.Altamira Therapeutics’ Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed JournalNASDAQ:CYTOAltamira Therapeutics Ltd
24/01/202414h47GlobeNewswire Inc.Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer TreatmentNASDAQ:CYTOAltamira Therapeutics Ltd
22/01/202423h02Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:CYTOAltamira Therapeutics Ltd
22/01/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CYTOAltamira Therapeutics Ltd
19/01/202422h40Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:CYTOAltamira Therapeutics Ltd
08/01/202423h02Edgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:CYTOAltamira Therapeutics Ltd
08/01/202414h47GlobeNewswire Inc.Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics SummitNASDAQ:CYTOAltamira Therapeutics Ltd
29/12/202314h47GlobeNewswire Inc.Altamira Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementNASDAQ:CYTOAltamira Therapeutics Ltd
11/12/202314h00GlobeNewswire Inc.Altamira Therapeutics Provides Investor and Business UpdateNASDAQ:CYTOAltamira Therapeutics Ltd
05/12/202318h54GlobeNewswire Inc.Altamira Therapeutics to Host Investor & Business Update Call on December 11thNASDAQ:CYTOAltamira Therapeutics Ltd
29/11/202316h20GlobeNewswire Inc.Altamira Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity RequirementNASDAQ:CYTOAltamira Therapeutics Ltd
17/11/202315h04GlobeNewswire Inc.Altamira Therapeutics Announces Partial Spin-Off of Bentrio® BusinessNASDAQ:CYTOAltamira Therapeutics Ltd
10/11/202314h47GlobeNewswire Inc.Altamira Therapeutics Announces European Patent Office Decision to Grant for Patent Application Covering Intranasal BetahistineNASDAQ:CYTOAltamira Therapeutics Ltd
14/09/202314h47GlobeNewswire Inc.Altamira Therapeutics Reports Additional Significant Efficacy Outcomes from Bentrio Clinical Trial in Seasonal Allergic RhinitisNASDAQ:CYTOAltamira Therapeutics Ltd
12/09/202313h30GlobeNewswire Inc.Altamira Therapeutics Provides Business Update and First Half 2023 Financial ResultsNASDAQ:CYTOAltamira Therapeutics Ltd
06/09/202314h47GlobeNewswire Inc.Altamira Therapeutics to Host First Half 2023 Financial Results and Business Update Call on September 12thNASDAQ:CYTOAltamira Therapeutics Ltd
23/08/202314h47GlobeNewswire Inc.Altamira Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13NASDAQ:CYTOAltamira Therapeutics Ltd
21/08/202313h31Edgar (US Regulatory)Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]NASDAQ:CYTOAltamira Therapeutics Ltd
20/07/202314h47GlobeNewswire Inc.Altamira Therapeutics and Pharma Nordic Collaborate for Marketing and Distribution of Bentrio in ScandinaviaNASDAQ:CYTOAltamira Therapeutics Ltd
17/07/202314h47GlobeNewswire Inc.Altamira Therapeutics Announces Publication of Positive Results from Clinical Trial with Bentrio in House Dust Mite Allergy in Leading Peer Reviewed JournalNASDAQ:CYTOAltamira Therapeutics Ltd
05/07/202314h47GlobeNewswire Inc.Altamira Therapeutics Announces Collaboration with Heqet Therapeutics on Nanoparticle-Delivered Non-Coding RNAs for Cardiac RegenerationNASDAQ:CYTOAltamira Therapeutics Ltd
27/06/202322h46Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:CYTOAltamira Therapeutics Ltd
 Showing the most relevant articles for your search:NASDAQ:CYTO

Dernières Valeurs Consultées

ASX
INNHD
Interstar Mill SR063L
USOTC
GWWTF
Growthpoint Properties (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés